ArticleCureus2025
Impact of Positive Peritoneal Cytology on Prognosis in Stage IA Endometrial Cancer: A Retrospective Cohort Study in the Era of Minimally Invasive Surgery.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognostic significance of positive peritoneal cytology (PC) in early-stage endometrial cancer remains debated, particularly following its exclusion from the 2008 International Federation of Gynecology and Obstetrics (FIGO) staging system. This study aimed to evaluate the impact of positive PC on recurrence and survival outcomes in patients with stage IA endometrial cancer, considering contemporary surgical practices, including minimally invasive surgery.
methodsThis retrospective cohort study included 325 patients diagnosed with stage IA endometrial cancer who underwent primary surgical treatment at Kagoshima University Hospital between 2010 and 2022. PC was assessed intraoperatively, and patients were stratified into positive and negative cytology groups. Clinicopathological characteristics, recurrence-free survival (RFS), and overall survival (OS) were compared using Kaplan‒Meier analysis. Cox proportional hazards regression was performed to identify independent prognostic factors.
resultsPositive PC was identified in 5.8% (19/325) of cases. Patients with positive cytology had significantly lower five-year RFS (72.7% vs. 93.7%, p = 0.0001) and OS (82.1% vs. 96.1%, p = 0.0001). Cox regression analysis identified positive PC as the strongest independent predictor of recurrence (HR 8.33, 95% CI: 2.41-25.8) and mortality (HR 14.2, 95% CI: 2.22-90.3). In addition, advanced age (≥60 years) was significantly associated with decreased survival.
conclusionPositive PC is a significant adverse prognostic factor in stage IA endometrial cancer, associated with increased recurrence and reduced survival. Future large-scale prospective studies are needed to determine its role in risk stratification and management of stage IA endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.